

European Society of Intensive Care Medicine (ESICM)  
2021 virtual symposium  
Tuesday 5 October, 2021 (12:30–13:30 [CEST])

## Managing bacterial and fungal infections in the ICU

Chair: Prof Philippe Montravers (France)

### Agenda

- 12:30–12:35 CEST**      »    **Welcome and introduction**  
*Prof Philippe Montravers, Paris, France (Chair)*
- 12:35–12:40 CEST**      »    **A hypothetical patient scenario in the ICU:  
What do we need to consider?**  
*Prof Philippe Montravers, Paris, France (Chair)*
- 12:40–13:00 CEST**      »    **Exploring the critical nature of patients in the ICU:  
Managing MDR Gram-negative infections**  
*Dr Andrew Shorr, Washington DC, United States*
- 13:00–13:20 CEST**      »    **Early suspicion of invasive mould disease in the ICU:  
Which patients are at risk?**  
*Dr Joost Wauters, Leuven, Belgium*
- 13:20–13:30 CEST**      »    **Panel discussion and Q&A**  
*All faculty*



ICU, intensive care unit; MDR, multidrug-resistant  
PP-CRB-GLB-0754;  
Date of preparation: August 2021.

This e-mail, its contents and any attached file are intended for the named addressee only. This e-mail contains information which may be confidential and which may also be privileged. If you have received this e-mail in error, please notify the sender immediately and then delete it from your system; you may not copy or use it in any way, or disclose, distribute or disseminate this e-mail or its content (or any parts of its content) to anyone. If you are the intended recipient, please only forward this message and/or any attached files to any relevant person on a need to know basis. All messages sent to and from Pfizer may be monitored to ensure compliance with internal policies and to protect our business. Emails are not secure and cannot be guaranteed to be error free as they can be intercepted, amended, lost or destroyed, or contain viruses. Anyone who communicates with us by e-mail is considered to accept these risks.

Please forward any safety event (adverse events/off label use/medication errors/exposure during pregnancy...) or quality & product complaints, immediately and directly to the Drug Safety Unit at [AEReporting@pfizer.com](mailto:AEReporting@pfizer.com)